دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action
Filippo Crea
doi : 10.1093/eurheartj/ehac479
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3185–3188
Is there an optimal diet for primordial prevention of atherosclerosis?Â
Kevin C Maki, Mary R Dicklin
doi : 10.1093/eurheartj/ehac434
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3189–3191
Danish scientist wins prestigious prize for piecing together the facts about remnant cholesterol
Judith Ozkan
doi : 10.1093/eurheartj/ehac429
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3192–3193
Aspirin: 1A @ 125Â
Carlo Patrono
doi : 10.1093/eurheartj/ehac416
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3194–3195
Atrial fibrosis detected by cardiac magnetic resonance in persistent atrial fibrillation: a useful risk stratifier but not ideal electrophysiological endpoint for catheter ablationÂ
Maria Lucia Narducci, Massimo Volpe
doi : 10.1093/eurheartj/ehac424
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3196–3197
The dawn of a new era of targeted lipid-lowering therapiesÂ
Lale Tokgözoğlu, Peter Libby
doi : 10.1093/eurheartj/ehab841
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3198–3208
Lipid risk factors for cardiovascular disease depend in part on lifestyle, but optimum control of lipids often demands additional measures. Low-density lipoprotein (LDL) doubtless contributes causally to atherosclerosis.
Screening in children for familial hypercholesterolaemia: start nowÂ
Urh Groselj, Albert Wiegman, Samuel S Gidding
doi : 10.1093/eurheartj/ehac224
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3209–3212
Prevalence of statin intolerance: a meta-analysisÂ
Ibadete Bytyçi, Peter E Penson, Dimitri P Mikhailidis, Nathan D Wong, Adrian V Hernandez, Amirhossein Sahebkar, Paul D Thompson, Mohsen Mazidi, Jacek Rysz, Daniel Pella, Željko Reiner, Peter P Toth, Maciej Banach
doi : 10.1093/eurheartj/ehac015
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3213–3223
Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events.
Statin intolerance: how common is it and how do we work with patients to overcome it?Â
Christopher P Cannon
doi : 10.1093/eurheartj/ehac156
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3224–3226
Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a centuryÂ
Alexandre M Bélanger, Leo E Akioyamen, Isabelle Ruel, Lindsay Hales, Jacques Genest
doi : 10.1093/eurheartj/ehac339
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3227–3239
Homozygous familial hypercholesterolaemia (HoFH) is an orphan disease defined by extreme elevations in low-density lipoprotein cholesterol, cutaneous xanthomas, and pre-mature atherosclerotic cardiovascular disease.
From supravalvular to valvular aortic stenosis: are statins contributing to the phenotypic shift in homozygous familial hypercholesterolaemia?Â
Archna Bajaj, Marina Cuchel
doi : 10.1093/eurheartj/ehac338
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3240–3242
Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysisÂ
Clara Marquina, Paul Lacaze, Jane Tiller, Moeen Riaz, Amy C Sturm, Mark R Nelson, Brian A Ference, Jing Pang, Gerald F Watts, Stephen J Nicholls, Sophia Zoungas, Danny Liew, John McNeil, Zanfina Ademi
doi : 10.1093/eurheartj/ehab770
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3243–3254
The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH).
Underdiagnosis of familial hypercholesterolaemia: innovation is overdueÂ
Corey K Bradley, Amit Khera, Ann Marie Navar
doi : 10.1093/eurheartj/ehab869
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3255–3257
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based studyÂ
Benjamin Nilsson Wadström, Anders Berg Wulff, Kasper Mønsted Pedersen, Gorm Boje Jensen, Børge Grønne Nordestgaard
doi : 10.1093/eurheartj/ehab705
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3258–3269
The atherogenic potential of cholesterol in triglyceride-rich lipoproteins, also called remnant cholesterol, is being increasingly acknowledged. Elevated remnant cholesterol is associated with increased risk of myocardial infarction and ischaemic stroke.
Risk of remnants and remnant risk in peripheral artery diseaseÂ
Connie N Hess, Marc P Bonaca
doi : 10.1093/eurheartj/ehab815
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Pages 3270–3272,
More than myocarditis, a rare adverse effect after the ChAdOx1 vaccine
Omar Gómez-Monterrosas, Georgina Loyola-RodrÃguez, David MartÃnez-Juárez
doi : 10.1093/eurheartj/ehac282
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Page 3273
Right atrial thrombus in transit
Erin M Schumer, Juan A Crestanello
doi : 10.1093/eurheartj/ehac346
European Heart Journal, Volume 43, Issue 34, 7 September 2022, Page 3274
